Drug Batch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs
- Completion of Initial DMT Research Drug Batch and Exercise of Warrants
Vancouver Canada based Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement with Psygen Labs Inc. Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances (“
DMT”) for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European Medicines Agency (EMA) regulatory framework.
On November 27, 2020, Psygen successfully completed the production of a non-GMP DMT research batch for delivery to the Company’s Contract Research Organization, CHDR’s partner pharmacy. The non-GMP DMT research batch will be shipped to CHDR upon receipt of Psygen� ....

United States , Timothy Ko , Danny Motyka , Joseph Cullen , University Of Alberta , Entheon Biomedical Corp , Psygen Labs Inc , Medicine Inc , Health Canada Office Of Controlled Substances , Centre For Human Drug Research , European Union , Stifel Nicolaus Canada Inc , Company Contract Research Organization , Numinus Wellness Inc , Research Drug Batch , Canaccord Genuity Corp , Field Trip Health Ltd , Investment Industry Regulatory Organization Of Canada , European Medicines Agency , Health Canada , Drug Batch , Entheon Biomedical , Psygen Labs , Contract Research Organization , Health Canada Office , Human Drug Research ,